Akebia Therapeutics, Inc. (AKBA)
NASDAQ: AKBA · Real-Time Price · USD
0.9066
-0.0128 (-1.39%)
At close: Aug 21, 2026, 4:00 PM EDT
0.911355
+0.0048 (0.52%)
After-hours: Aug 21, 2026, 7:31 PM EDT
Akebia Therapeutics Stock Forecast
Stock Price Forecast
According to 5 analysts polled by S&P Global, Akebia Therapeutics stock has a consensus rating of "Buy" and an average price target of $3.80. The average 1-year stock price forecast is 319.15% higher than the current stock price, while the lowest is $1.00 (+10.30%) and the highest is $6.00 (+561.81%).
Price Target: $3.80 (+319.15%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Akebia Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 3 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy Maintains $4 | Buy | Maintains | $4 | +341.21% | Aug 17, 2026 |
| Leerink Partners | Leerink Partners | Hold Downgrades $1 | Hold | Downgrades | $1 | +10.30% | Aug 7, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $6 | Buy | Reiterates | $6 | +561.81% | Aug 6, 2026 |
| BTIG | BTIG | Buy Reiterates $4 | Buy | Reiterates | $4 | +341.21% | Aug 6, 2026 |
Financial Forecast
Revenue This Year
196.84M
from 236.20M
Decreased by -16.66%
Revenue Next Year
140.04M
from 196.84M
Decreased by -28.86%
EPS This Year
-0.16
from -0.02
EPS Next Year
-0.33
from -0.16
EPS and Forward PE are based on non-GAAP adjusted numbers.